The approval is based on results from the Phase III FLOW trial demonstrating Ozempic reduced the risk of severe kidney outcomes by 24% compared to placebo, including kidney failure, reduction in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback